Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Lee430on May 04, 2023 8:48pm
66 Views
Post# 35431736

RE:Proxy Votes

RE:Proxy VotesWell based on SPCEO's message, reluctantely I will likely change my votes to withold on Friday as a yes vote is just to much of a strech for me.

SPCEO1 wrote: I had a good conversation with Dawn yesterday and it is clear she and the board see the unfavorable direction of many of the shareholder votes and are going to do their best to sort out the concerns shareholders have thereby indicated as best possible. Coming out of our conversation, I am hopeful we will see some positive changes in the not too distant future. As I see it, TH-1902 is the key determinant of the stock's future. If it succeeds, the stock will move considerably higher. If it fails, a lot of personnel changes at THTX will likely occur anyway as the company's opportunity set would be much redced and some in leadership would likely move on to greener pastures of their own accord. My best guess is THTX has the best chance of turning TH-1902 into something successful if we do not change the horses that carried us halfway across the stream right in the middle of that stream where the waters are most turbulent. Big governance changes now could disrupt TH-1902's progress as management would need to divert attention away from TH-1902. So, we are voting in favor of all items on the proxy and trusting the board to make the adjustments many shareholders have already indicated need to be made. I think this is the best route to take to have the best chance of investment success. My emotions may be arguing with me on that conclusion but reason suggests otherwise. Moreover, I do expect the company to make changes some of us might have be trying to vote into existence, so there is less of a need to create the chaos such votes could create when the objectives have a good chance of being achieved without creating any such chaos.




<< Previous
Bullboard Posts
Next >>